Provasis Therapeutics

Provasis Therapeutics is a biotechnology company dedicated to the discovery and development of innovative small molecule therapies for immune-mediated inflammatory diseases. The company was established by a veteran leadership team with a proven track record in the GPCR space, having previously led Receptos and Gossamer Bio. Provasis's lead candidate, PRV-001, is a highly selective agonist of GPR35, a target genetically linked to inflammatory bowel disease. By targeting this receptor, the company aims to promote mucosal healing and restore the epithelial barrier in patients suffering from ulcerative colitis. Headquartered in San Diego, Provasis is supported by a syndicate of leading venture capital firms to advance its pipeline into clinical trials.